ALLOVIR INC (ALVR)
US0198181036 - Common Stock
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CDE, ALVR, PULM, ENTO on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IPXX, YOTA, ALVR on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AE, EMKR, STAF, ALVR on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALVR, CDMO, EMKR on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc. - ALVR
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EMKR and ALVR on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EMKR and ALVR on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Let's take a look at the stocks that are in motion in today's session.
Top movers in Friday's session
These stocks are gapping in today's session
Gapping stocks in Friday's session
ALVR Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of AlloVir, Inc. Is Fair to Shareholders
Get insights into the top gainers and losers of Friday's pre-market session.
Get insights into the top gainers and losers of Friday's pre-market session.
AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina
Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a novel, differentiated and...
ALVR Stock Earnings: AlloVir Beats EPS for Q2 2024
ALVR stock results show that AlloVir beat analyst estimates for earnings per share the second quarter of 2024.
ALVR Stock Earnings: AlloVir Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips AlloVir (NASDAQ:ALVR) just reported results for the second quarter of 2024.Allo...
ALVR Stock Earnings: AlloVir Misses EPS for Q1 2024
ALVR stock results show that AlloVir missed analyst estimates for earnings per share the first quarter of 2024.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALVR
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ: ALVR). The class...
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir
ALVR DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR
WHY: NEW YORK, NY - (NewMediaWire) - March 18, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both dates inclusive (the “Class Period”), of the important March 19, 2024 lead plaintiff deadline.
ALVR DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ALVR Stock Earnings: AlloVir Misses EPS for Q4 2023
ALVR stock results show that AlloVir missed analyst estimates for earnings per share the fourth quarter of 2023.
ALVR Stock Earnings: AlloVir Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips AlloVir (NASDAQ:ALVR) just reported results for the fourth quarter of 2023.Allo...
ALVR DEADLINE: ROSEN, A RANKED AND LEADING FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ALVR
WHY: NEW YORK, NY - (NewMediaWire) - March 17, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both dates inclusive (the “Class Period”), of the important March 19, 2024 lead plaintiff deadline.
ALVR DEADLINE: ROSEN, A RANKED AND LEADING FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ALVR
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ALVR DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ALVR
WHY: NEW YORK, NY - (NewMediaWire) - March 16, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both dates inclusive (the “Class Period”), of the important March 19, 2024 lead plaintiff deadline.
ALVR DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ALVR
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ALVR DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ALVR
WHY: NEW YORK, NY - (NewMediaWire) - March 15, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both dates inclusive (the “Class Period”), of the important March 19, 2024 lead plaintiff deadline.
ALVR DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ALVR
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ALVR LAWSUIT ALERT: Levi & Korsinsky Notifies AlloVir, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ: ALVR) of a class action securities lawsuit....
ALVR DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR
WHY: NEW YORK, NY - (NewMediaWire) - March 14, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both dates inclusive (the “Class Period”), of the important March 19, 2024 lead plaintiff deadline.
ALVR DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Holzer & Holzer, LLC Reminds Shareholders of the March 19, 2024 Lead Plaintiff Deadline in the AlloVir, Inc. (ALVR) Class Action - Nationally Ranked Investors Rights Firm Encourages Investors With Significant Losses to Contact the Firm
ATLANTA, GA - (NewMediaWire) - March 14, 2024 - Holzer & Holzer, LLC reminds shareholders that a class action lawsuit has been filed against AlloVir, Inc. (“AlloVir” or the “Company”) (NASDAQ: ALVR). The lawsuit alleges Defendants made materially false and misleading statements and/or failed to disclose material information regarding the Company’s business, operations, and prospects, including allegations that: (i) the posoleucel Phase 3 Studies were unlikely to meet their primary endpoints; (ii) as a result, it was likely that the Company would ultimately discontinue the posoleucel Phase 3 studies; (iii) accordingly, AlloVir overstated the efficacy and clinical and/or commercial prospects of posoleucel; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Holzer & Holzer, LLC Reminds Shareholders of the March 19, 2024 Lead Plaintiff Deadline in the AlloVir, Inc. (ALVR) Class Action - Nationally Ranked Investors Rights Firm Encourages Investors With Significant Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir
ALVR IMPORTANT DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022...